Episode summary
Can a GLP-1 Pill Revive Novo Nordisk? | Prof G Markets
Prof G Markets
· · 27 min · Hosts: Ed Elson, Scott Galloway · Guests: Alex Heath, Jared Holz
Summary
Nvidia dominated the CES conversation after Jensen Huang said the company’s newest chip, Rubin, is in full production and pushed into automotive AI, including a Mercedes-Benz rollout this year. Alex Heath argued the bigger story is not a near-term Tesla-style autonomy business, but Nvidia using verticals like cars and robotics to gather data, improve chips, and deepen its core GPU moat. He also described CES as full of AI wearables, glasses, and robotics demos, but said much of the hardware still looks like vaporware.
Heath framed Nvidia’s reported deal with Grok as a “reverse aqua hire”: a talent grab dressed up as a licensing transaction. He said Nvidia wants Grok’s team to fix inference and latency problems as AI workloads move from training into production. He also said the structure suggests Jensen Huang is in founder mode and may keep doing large deals.
The second half focused on Novo Nordisk’s Wegovy pill and what it could mean for GLP-1 adoption. Jared Holz said the oral version matters because it lowers the cost and removes the needle barrier, which could open the market to more patients even if efficacy is not identical to injectables. The host argued the pill eliminates a major adoption constraint and could push GLP-1 usage much higher, while Holz said the biggest upside for Novo depends on how much share the oral version can take versus Eli Lilly’s competing pill.
Key takeaways
- Alex Heath said Nvidia’s autonomy push is less about building a standalone car business and more about collecting data to improve future chips.
- Heath described Nvidia’s Grok deal as a “reverse aqua hire,” with the real goal being to acquire talent for inference and latency.
- Jared Holz said oral GLP-1s matter because the category is huge, consumer-like, and the pill form can reach patients who avoid injections.
- Holz said Novo Nordisk’s low expectations versus Eli Lilly could help the stock if Wegovy oral performs well.
- The host argued Wegovy’s pill form removes a major needle-phobia barrier and could materially expand GLP-1 adoption in the U.S.
Notable quotes
“I call these reverse aqua hires and I'm glad that the name has actually stuck since I coined it about a year and a half ago”
“they don't actually care about the tech, they care about the talent, uh, and leave the kind of flaming husk, if you will, of like the thing left behind”
“the expectations around Lily's Oral or for Gibron and then the oral we go out of Nova Nordis, the the chasm between the two couldn't be bigger”
“What we have here is a seemingly small and uninteresting issue, which is in fact a pretty gigantic issue”
How the episode opens
Today's number, 120 million. That's how many dollars Alex Co-op spent on a Colorado compound, which used to be the home of a silent monk community. Palunteer Investor relations say they support the transaction, but have requested that the vow of silence be made transferable.
Welcome to Profy Markets. I'm Edson. It is January 7th.
Let's check in on yesterday's market vitals. The major indices all posted strong gains. The Dow notched its first close above 49,000.
The S&P 500 also hit a record closing high. Meanwhile, oil prices gave up Monday's advance. And finally, gold, silver, and copper extended their rallies.
Okay, what else is happening? The biggest celebration of consumer tech, the Consumer Electronics Show or CES, kicked off in Las Vegas this week. It is an opportunity for tech companies to showcase their latest innovations.
And so far, it is Nvidia that is dominating the headlines. Nvidia's CEO, Jensen Huang, opened the event with an announcement that their most advanced chip yet, the Reuben model, is in full production. He also introduced AI models for autonomous vehicles.
and he said, quote, "The chat GBT moment for physical AI is here, and it appears to be happening fast because Mercedes-Benz will begin shipping cars with Nvidia's technology this year. So, lots happening at CES. We wanted to get a sense of what else is happening.
So, we are speaking with someone who was there right now, Alex Heath, author of the Sources Newsletter and host of the Access podcast, joins us from Vegas. Alex, welcome back and happy new year. Happy new year, Ed.
I am doing CS like I always do, which is I try to avoid the show floor as much as possible, but uh I am managing to head over there right after this conversation.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- glp-1 pills
- novo nordisk
- wegovy
- ai chips
- healthcare equity
Companies and tickers mentioned
- NVDA
- NVO
- Nvidia
- Novo Nordisk
Watch the episode
Watch “Can a GLP-1 Pill Revive Novo Nordisk? | Prof G Markets” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Prof G Markets
-
Big Tech Is Now Advising the White House — What Could Go Wrong? | Prof G Markets -
Trump Says the Economy Is Strong — Voters Disagree | Prof G Markets -
The AI Divide: Who Wins and Who Gets Replaced | Prof G Markets -
The $1.5B Insider Trade Before Trump’s Iran Post | Prof G Markets -
Is the Oil Crisis About to Break Global Supply Chains? | Prof G Markets -
$1T Moved on Iran “Talks” — Did They Even Happen? | Prof G Markets
Prof G Markets, this episode and its artwork belong to Vox Media Podcast Network. Octagon is not affiliated with the show; this page is an independent summary.
